Tesamorelin
Compounded in a licensed US 503A pharmacy 🇺🇸
Growth Hormone Releasing Research Peptide.
Tesamorelin is a stabilized synthetic analogue of growth hormone-releasing hormone (GHRH) with a trans-3-hexenoic acid modification at the N-terminus for improved plasma stability, studied in somatotropic axis research. Preclinical researchers investigate its interactions with pituitary GHRH receptors, pulsatile GH secretion dynamics, and downstream IGF-1 axis regulation in in vitro and animal model systems. It is also studied in visceral adipose tissue metabolism research in preclinical settings, where GHRH receptor activation and lipid mobilization pathways are examined. Supplied as a lyophilized peptide of analytical purity for laboratory research use only. For in vitro and preclinical investigation; not for human use.
- 5mg lyophilized format
- Precision measured
- Stored under sterile conditions
- Research use only
Independently verified by Freedom Diagnostics via HPLC and mass spec. Every vial carries a unique accession number you can look up directly with the lab.
- 2-day shipping nationwide, flat $12.50
- Plain, discreet packaging. No product names on the outside.
- Tracking emailed the moment your order ships.
About Tesamorelin
Tesamorelin is a synthetic analog of growth hormone-releasing hormone (GHRH) in which the native 44-amino acid GHRH(1-44) sequence is stabilized by the addition of a trans-3-hexenoic acid group at the N-terminus. This modification protects the peptide from rapid enzymatic degradation by dipeptidyl peptidase IV (DPP-IV), extending its preclinical half-life relative to native GHRH. Tesamorelin acts on pituitary somatotroph cells to stimulate growth hormone (GH) secretion in a pulsatile, physiologically mimetic pattern.
In research settings, Tesamorelin is studied as a tool compound for investigating the GH/IGF-1 axis and its downstream effects on lipid metabolism, particularly in models relevant to visceral adipose tissue regulation. Published research has examined changes in GH pulsatility patterns, IGF-1 production, and adipokine profiles in response to Tesamorelin treatment in preclinical and early-phase human study contexts.
Tesamorelin holds an approved regulatory status in certain jurisdictions for a specific clinical indication, making it one of the few research peptides with a defined clinical data package. Despite this, supply of Tesamorelin as a research compound is intended for laboratory research use within formally supervised scientific programs and not for self-administration or unsupervised use.
Buy Tesamorelin online
Tesamorelin is in stock and available to buy online from Optimum ReGen Peptides — a real American research-peptide company with a physical storefront in Medford, Oregon, not an anonymous overseas dropshipper. Priced from $50, every order ships within two business days, flat $12.50 nationwide, in plain discreet packaging with tracking.
As your Tesamorelin supplier we back every batch with a third-party certificate of analysis and compound in a licensed US 503A pharmacy. Vials are supplied lyophilized at analytical purity for laboratory and research use only, not for human consumption.
Researched For
Tesamorelin is used as a GHRH analog in studies examining pituitary somatotroph function, GH pulse amplitude and frequency analysis, and downstream IGF-1 and IGFBP-3 production in preclinical and study-population samples.
Research has examined Tesamorelin's effects on visceral fat depots in both animal models and study populations, characterizing changes in adipocyte lipid turnover markers, adipokine profiles, and imaging-quantified fat volume.
Researchers have studied Tesamorelin in the context of dyslipidemia-associated research, examining changes in triglyceride levels, lipoprotein profiles, and hepatic lipid accumulation markers as downstream endpoints of GH axis stimulation.
Given GH/IGF-1 axis involvement in neural tissue maintenance, researchers have investigated Tesamorelin in models examining hippocampal neurogenesis markers, cognitive performance endpoints, and amyloid-related pathway markers in aging animal models.
Laboratory and study-based research has used Tesamorelin to examine how GH axis stimulation interacts with insulin sensitivity markers, glucose homeostasis endpoints, and adipose tissue inflammatory gene expression patterns.
How It Is Studied
In preclinical studies, Tesamorelin is administered by subcutaneous injection to rodent models, with blood sampling at defined intervals to construct GH pulse profiles using ultrasensitive immunoassays. IGF-1 and IGFBP-3 serum levels are quantified by ELISA as downstream markers of somatotroph axis stimulation. Adipose tissue is harvested for gene expression profiling using RT-PCR panels targeting lipogenic and lipolytic enzyme genes.
Researchers characterize Tesamorelin's DPP-IV resistance by incubating the compound in plasma preparations and comparing intact peptide recovery over time against unmodified GHRH using LC-MS/MS. This confirms that the N-terminal modification confers the intended enzymatic stability and validates the pharmacokinetic rationale for the structural design.
In metabolic research designs, indirect calorimetry, body composition analysis by DEXA or MRI, and comprehensive metabolic panel measurement are used as systemic endpoint readouts in animal model studies. Researchers also examine pituitary somatotroph density and GH granule content by electron microscopy in long-term treatment cohorts to assess gland-level response to chronic GHRH receptor stimulation.
Specifications
| Form | Lyophilized powder |
|---|---|
| Purity | >= 99% (HPLC) |
| Chain length | 44 amino acids (GHRH analog) |
| N-terminal modification | trans-3-hexenoic acid conjugate |
| Storage (lyophilized) | -20 °C, sealed, light-protected |
| Storage (reconstituted) | 4 °C, use within 24 hours (no preservative) |
Storage & Handling
Lyophilized Tesamorelin should be stored at -20 °C, protected from light and humidity, in sealed vials. The lyophilized form is stable for extended periods under these conditions. For reconstitution, sterile water for injection or the provided diluent is used; the reconstituted solution should be used promptly, ideally within 24 hours when no preservative is present, or within the timeframe specified by the study protocol.
Tesamorelin solutions should not be vigorously shaken, as mechanical agitation can disrupt protein structure. Gentle swirling is the recommended mixing method. Any unused reconstituted solution should be discarded at the end of the working day. Pre-aliquoting the lyophilized powder into single-experiment portions before any reconstitution minimizes waste and cycle-related degradation.
Frequently Asked Questions
How does Tesamorelin differ from native GHRH in research?+
What pituitary cell type does Tesamorelin act on?+
Does Tesamorelin directly stimulate IGF-1 production?+
Has Tesamorelin been studied in human populations?+
What makes Tesamorelin relevant to metabolic research?+
Related research compounds
